(+)-Validoxylamine A was synthesized by selective deoxygenation of (+)-validoxylamine B derivative, which was obtained by the coupling of the partially protected (+)-valienamine and (1R,2S,5R,7R,8R,9R,10R)-8,9-dibenzyloxy-5-phenyl-4,6,11-trioxatricyclo[8.1.0.02,7]undecane. The present synthesis constitutes a formal totalsynthesis of antibiotic validamycin A.
(+)-Validoxylamine A 通过选择性脱氧合成 (+)-validoxylamine B 衍生物,该衍生物由部分保护的 (+)-valienamine 与 (1R,2S,5R,7R,8R,9R,10R) 偶联获得)-8,9-二苄氧基-5-苯基-4,6,11-三氧杂三环[8.1.0.02,7]十一烷。本合成构成了抗生素有效霉素 A 的正式全合成。
Methods of producing validamycin A analogs and uses thereof
申请人:State of Oregon acting by and through the State Board of Higher Education on behalf of Oregon State University
公开号:US08101732B2
公开(公告)日:2012-01-24
This disclosure relates to validamycin A biosynthesis and in particular, to methods of producing validamycin A analogs and uses thereof. In a particular example, a method for making a validamycin A analog includes transforming a host cell with one or more recombinant DNA vectors to produce a valN-inactivated mutant; and culturing the valN-inactivated mutant in a culture medium to produce a validamycin A analog, such as 1,1′-bis-valienamine and validienamycin, and their conversion to valienamine. The present disclosure further relates to compositions including such compounds as well as methods of using the compositions, such as for antifungal agents.